个股 · 美股
共 928 份研报 · 国内 224 · 国外 682 · 个股
Hemab Therapeutics（COAG.US）：首次覆盖给予“增持”，具备独特优势的出血性疾病研发管线
Initiating Overweight – A Pipeline for Bleeding Disorders with the X-Factor
摩根大通·2026-10-15·28 页·美股
渗透率测算推演：通往400万例美国手术之路
Intuitive Surgical Inc (ISRG.O): Playing Around with Penetration Maths...The Road to 4 Million US Procedures
瑞银·2026-10-13·27 页·美股
瑞银-Vylor（VYLR.US）：播撒未来增长种子，首次覆盖给予“买入”评级
Vylor Inc: Seeding the Growth of Tomorrow; Initiate Buy
瑞银·2026-10-12·49 页·美股
瑞银-Tectonic Therapeutic（TECX.US）：临床试验成功也可能不及预期：首次覆盖给予“中性”评级
Tectonic Therapeutic Inc: A Positive Trial Could Still Disappoint - Initiate at Neutral
瑞银·2026-10-11·51 页·美股
Spyre Therapeutics（SYRE.US）：仍有更多机会，首次覆盖给予“买入”评级
Spyre Therapeutics: There's More to Play For - Initiate at Buy
瑞银·2026-10-11·71 页·美股
Shattuck Labs（STTK.US）：暂离焦点但未退出TL1A赛道，首次覆盖给予"买入"评级
Shattuck Labs Inc (STTK): Off the Radar, but Not Out of the (TL1A) Race - Initiate at Buy
瑞银·2026-10-11·52 页·美股
Protagonist Therapeutics（PTGX.US）：特许权使用费支撑可持续性，首次覆盖给予“买入”评级
Protagonist Therapeutics (PTGX.US): Royalties Funding Repeatability - Initiate at Buy
瑞银·2026-10-11·65 页·美股
Odyssey Therapeutics（ODTX.US）：IBD领域前景广阔的全新口服疗法，催化剂在2027年下半年——首次覆盖给予“买入”评级
Odyssey Therapeutics Inc (ODTX): Promising New Oral Approach in IBD; Catalyst in 2H27 - Initiate at Buy
瑞银·2026-10-11·48 页·美股
Ocular Therapeutix（OCUL.US）：差异化长效视网膜疗法临近上市，首次覆盖给予"买入"评级
Ocular Therapeutix Inc: Differentiated Long-Acting Retina Therapy Approaching Market - Initiate at Buy
瑞银·2026-10-11·53 页·美股
Monte Rosa Therapeutics（GLUE.US）：ZEUS并未推翻炎症相关假说，MRT-8102提供差异化切入角度——首次覆盖给予“买入”评级
Monte Rosa Therapeutics Inc (GLUE): ZEUS Didn't Break the Inflammation Thesis; MRT-8102 Offers a Different Angle - Assume at Buy
瑞银·2026-10-11·61 页·美股
Kardigan（KARD.US）：2027年上半年催化剂前的具吸引力入场点，首次覆盖给予“买入”评级
Kardigan Inc: Attractive Entry Point Ahead of 1H27 Catalysts - Initiate at Buy
瑞银·2026-10-11·64 页·美股
清凉慰藉，热门商业机遇：首次覆盖并给予"买入"评级
AbCellera Biologics Inc: Cool Relief, Hot Commercial Opportunity - Initiate at Buy
瑞银·2026-10-11·58 页·美股
Definium Therapeutics（DFTX.US）神经精神病学领域值得进行的投资：给予增持初始评级
Definium Therapeutics (DFTX): The Trip Worth Taking in Neuropsychiatry; Initiating at Overweight
摩根大通·2026-10-09·74 页·美股
C4 Therapeutics（CCCC.US）：首次覆盖给予“增持”评级，看好Cemsidomide在多发性骨髓瘤中的潜力
C4 Therapeutics: Initiating at Overweight on Cemsidomide's Potential in Multiple Myeloma
摩根大通·2026-10-09·28 页·美股
萨瓦拉公司（SVRA.US）：Molbreevi能否赢得下一个（呼吸）肺病学批准？——首次覆盖并给予增持评级
Could Molbreevi Score the Next R(Air) Pulmonology Approval? — Initiating Coverage at OW
摩根大通·2026-10-07·30 页·美股
盛美半导体：清洗先锋拓展业务版图
ACM Research (ACMR.OQ): Cleaning pioneer expanding footprint
野村证券·2026-10-07·36 页·美股
霍尼韦尔航空航天（HONA）首次覆盖给予中性评级：成长型市场产品优质，但关键绩效指标基准低于行业平均
Honeywell Aerospace Inc (HONA): Initiate at Neutral given quality products in growth markets, but below industry average KPI bench-marking
高盛·2026-10-07·23 页·美股
Stevanato（STVN）首次覆盖：优势澄澈如玻璃；静待菲舍尔工厂产能爬坡（给予“持有”评级，目标价22美元）
Stevanato (STVN): Strengths as Clear as Glass; Awaiting Fishers Ramp
德意志银行·2026-10-07·63 页·美股
GE Vernova（GEV）：电力服务业务——一份持续兑现价值的“礼物”
GE Vernova (GEV): Power Services - The gift that keeps on giving
伯恩斯坦·2026-10-06·22 页·美股
全球高端美妆领导者开启新篇章
Estee Lauder Cos Inc (EL US): A New Chapter for the Global Prestige Beauty Leader
华泰证券·2026-10-06·66 页·美股
显示 21 - 40 条，共 928 条